NCT04669951View on ClinicalTrials.gov

Urokinase-type Plasminogen Activator Receptor and Gastroesophageal Cancer

NACompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

November 18, 2019

Primary Completion Date

November 30, 2020

Study Completion Date

November 30, 2020

Conditions
Esophagus Cancer, Adenocarcinoma
Interventions
OTHER

uPAR immunohistochemistry

Resected esophageal cancer will be qualitatively and semi-quantitatively analyzed for uPAR expression

Trial Locations (1)

2100

Rigshospitalet, Copenhagen

All Listed Sponsors
lead

Michael Patrick Achiam

OTHER

NCT04669951 - Urokinase-type Plasminogen Activator Receptor and Gastroesophageal Cancer | Biotech Hunter | Biotech Hunter